Objective. There is no reliable treatment for men with idiopathic infertility, but the relationship between severe sperm production and the ratio of estrogen to testosterone levels has been shown. Aromatase is an enzyme that plays an important role in converting testosterone to estradiol and androstenedione to estrogen. Aromatase inhibitors can increase testosterone and androgen production without increasing the amount of estrogen in circulation. The aim of this study was to evaluate the effect of aromatase inhibitor letrozole on the male infertility.
Method. This pre- and post-quasi-experimental clinical trial was carried out on 41 men with an infertility diagnosis. The basic hormonal profile included FSH, LH, testosterone, and estradiol. The ratio of testosterone to serum estradiol was also calculated and recorded. The sperm analysis was performed before the treatment and the seminal parameters were evaluated and recorded. Patients were then treated with letrozole 2.5 mg daily for 4 months. At the end of 4th months, the hormonal profile was studied and seminal analysis performed and recorded.
Results. The levels of FSH, LH, testosterone, and estradiol, and the ratio of testosterone to estradiol increased significantly after letrozole treatment. The sperm concentration, sperm motility, and sperm forward motion significantly increased after letrozole treatment. Sperm morphology only lightly altered.
Conclusion. The ratio of testosterone to estradiol levels in infertile men treated with aromatase inhibitor improved and caused changes in sperm parameters. Letrozole may be used to improve sperm parameters in infertile men with low serum testosterone to estradiol ratio.
Clark RV Sherins RJ. Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor testolactone. Results of a double-blinded randomized placebo-controlled trial with crossover. J Androl 10 240–247 1989.
Fejes I Koloszar S Zavaczki Z Daru J Szollosi J Pal A. Effect of body weight on testosterone/estradiol ratio in oligozoospermic patients. Arch Androl 52 97–102 2006.
Gregoriou O Bakas P Grigoriadis C Creatsa M Hassiakos D Creatsas G. Changes in hormonal profile and seminal parameters with use of aromatase inhibitors in management of infertile men with low testosterone to estradiol ratios. Fertil Steril 98 48–51 2012.
Haider H Solanki KS Pal G Singh MK Kothari JS Agarwal VK. Process for the preparation of letrozole. WO/2007/054964 PCT/IN2006/000337 2007. https://patentscope.wipo.int › search › detail.
Haynes BP Jarman M Dowsett M Mehta A Lonning PE Griggs LJ Jones A Powles T Stein R Coombes RC. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-26-dione in patients with postmenopausal breast cancer. Cancer Chemother Pharmacol 27 367–372 1991.
Inkster S Yue W Brodie A. Human testicular aromatase: immunocytochemical and biochemical studies. J Clin Endocrinol Metab 80 1941–1947 1995.
Ng KK Donat R Chan L Lalak A Di Pierro I Handelsman DJ. Sperm output of older men. Hum Reprod 19 1811–1815 2004.
Patry G Jarvi K Grober ED Lo KC. Use of the aromatase inhibitor letrozole to treat male infertility. Fertil Steril 92 829.e1–829.e2 2009.
Pavlovich CP King P Goldstein M Schlegel PN. Evidence of a treatable endocrinopathy in infertile men. J Urol 165 837–841 2001.
Raman JD Schlegel PN. Aromatase inhibitors for male infertility. J Urol 167 624–649 2002.
Saylam B Efesoy O Cayan S. The effect of aromatase inhibitor letrozole on body mass index serum hormones and sperm parameters in infertile men. Fertil Steril 95 809–811 2011.
Smith IE Norton A. Fadrozole and letrozole in advanced breast cancer: clinical and biochemical effects. Breast Cancer Res Treat 49 S67–S77 1998.
Wang JM Gu CH Tao L Wu XL. Effect of surgery and efferent duct ligation on testicular blood flow and testicular steroidogenesis in the rat. J Reprod Fertil 73 191–196 1985.